Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia
Angiology · 2024
DOI: 10.1177/00033197241235757 ↗Kurz gefasst
Leserbrief in der Zeitschrift Angiology, 2024. Verfasst von Xiaocong Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zibo Central Hospital, Zibo, China. Hauptthemen laut MEDLINE: Pre-Eclampsia, Biomarkers, Endothelium, Vascular, Intercellular Signaling Peptides and Proteins. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Zibo Central Hospital, Zibo, China.
- Department of Clinical Laboratory, Zibo Occupational Disease Prevention and Control Hospital, Zibo, China.
- Department of Jahwa ward, Liaocheng Dongchangfu District Maternal and Child Health Hospital, Liaocheng, China.
ORCID-Profile: Cuiping Lv
Zitieren
APA
Liu, X., Zhang, Y., Li, Y., & Lv, C. (2024). Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia. Angiology. https://doi.org/10.1177/00033197241235757
Vancouver
Liu X, Zhang Y, Li Y, Lv C. Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia. Angiology. 2024. doi:10.1177/00033197241235757
BibTeX
@article{Liu2024,
author = {Liu, Xiaocong and Zhang, Yanan and Li, Yan and Lv, Cuiping},
title = {Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia},
journal = {Angiology},
year = {2024},
doi = {10.1177/00033197241235757}
}
EUVIMED